Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 13 to 24 of 1876 entries
Sorted by: Best Match Show Resources per page
Rifabutin-based 10-day and 14-day triple therapy as a third-line and fourth-line regimen for Helicobacter pylori eradication: A pilot study.

United European gastroenterology journal

Mori H, Suzuki H, Matsuzaki J, Tsugawa H, Fukuhara S, Miyoshi S, Hirata K, Seino T, Matsushita M, Nishizawa T, Masaoka T, Kanai T.
PMID: 27403304
United European Gastroenterol J. 2016 Jun;4(3):380-7. doi: 10.1177/2050640615618043. Epub 2015 Nov 13.

BACKGROUND AND AIM: This prospective randomized study was designed to assess the efficacy of 10-day and 14-day rifabutin-based triple therapy as a third- or fourth-line rescue therapy.METHODS: Patients who failed first- and second-line eradication therapy were enrolled. H. pylori...

Cite
Mori H, Suzuki H, Matsuzaki J, et al. Rifabutin-based 10-day and 14-day triple therapy as a third-line and fourth-line regimen for Helicobacter pylori eradication: A pilot study. United European Gastroenterol J. 2015;4(3):380-7doi: 10.1177/2050640615618043.
Mori, H., Suzuki, H., Matsuzaki, J., Tsugawa, H., Fukuhara, S., Miyoshi, S., Hirata, K., Seino, T., Matsushita, M., Nishizawa, T., Masaoka, T., & Kanai, T. (2016). Rifabutin-based 10-day and 14-day triple therapy as a third-line and fourth-line regimen for Helicobacter pylori eradication: A pilot study. United European gastroenterology journal, 4(3), 380-7. https://doi.org/10.1177/2050640615618043
Mori, Hideki, et al. "Rifabutin-based 10-day and 14-day triple therapy as a third-line and fourth-line regimen for Helicobacter pylori eradication: A pilot study." United European gastroenterology journal vol. 4,3 (2016): 380-7. doi: https://doi.org/10.1177/2050640615618043
Mori H, Suzuki H, Matsuzaki J, Tsugawa H, Fukuhara S, Miyoshi S, Hirata K, Seino T, Matsushita M, Nishizawa T, Masaoka T, Kanai T. Rifabutin-based 10-day and 14-day triple therapy as a third-line and fourth-line regimen for Helicobacter pylori eradication: A pilot study. United European Gastroenterol J. 2016 Jun;4(3):380-7. doi: 10.1177/2050640615618043. Epub 2015 Nov 13. PMID: 27403304; PMCID: PMC4924440.
Copy Download .nbib Format: NLM
Outcomes of a Randomized Controlled Trial Comparing Modified High Dose Omeprazole and Amoxicillin Triple Therapy with Standard Triple Therapy for Helicobacter Pylori Eradication.

Asian Pacific journal of cancer prevention : APJCP

Chunlertlith K, Limpapanasit U, Mairiang P, Vannaprasaht S, Tassaneeyakul W, Sangchan A, Sawadpanich K, Suttichaimongkol T, Pongpit J, Pattarapongsin M.
PMID: 28545189
Asian Pac J Cancer Prev. 2017 Apr 01;18(4):927-932. doi: 10.22034/APJCP.2017.18.4.927.

Background: Helicobacter pylori (H. pylori) infection is related to peptic ulcer diseases and gastric cancer and eradication of H. pylori should be expected to decrease the risk of their development. Factors affecting H. pylori eradication are antibiotic resistance, CYP2C19...

Cite
Chunlertlith K, Limpapanasit U, Mairiang P, et al. Outcomes of a Randomized Controlled Trial Comparing Modified High Dose Omeprazole and Amoxicillin Triple Therapy with Standard Triple Therapy for Helicobacter Pylori Eradication. Asian Pac J Cancer Prev. 2017;18(4):927-932doi: 10.22034/APJCP.2017.18.4.927.
Chunlertlith, K., Limpapanasit, U., Mairiang, P., Vannaprasaht, S., Tassaneeyakul, W., Sangchan, A., Sawadpanich, K., Suttichaimongkol, T., Pongpit, J., & Pattarapongsin, M. (2017). Outcomes of a Randomized Controlled Trial Comparing Modified High Dose Omeprazole and Amoxicillin Triple Therapy with Standard Triple Therapy for Helicobacter Pylori Eradication. Asian Pacific journal of cancer prevention : APJCP, 18(4), 927-932. https://doi.org/10.22034/APJCP.2017.18.4.927
Chunlertlith, Kitti, et al. "Outcomes of a Randomized Controlled Trial Comparing Modified High Dose Omeprazole and Amoxicillin Triple Therapy with Standard Triple Therapy for Helicobacter Pylori Eradication." Asian Pacific journal of cancer prevention : APJCP vol. 18,4 (2017): 927-932. doi: https://doi.org/10.22034/APJCP.2017.18.4.927
Chunlertlith K, Limpapanasit U, Mairiang P, Vannaprasaht S, Tassaneeyakul W, Sangchan A, Sawadpanich K, Suttichaimongkol T, Pongpit J, Pattarapongsin M. Outcomes of a Randomized Controlled Trial Comparing Modified High Dose Omeprazole and Amoxicillin Triple Therapy with Standard Triple Therapy for Helicobacter Pylori Eradication. Asian Pac J Cancer Prev. 2017 Apr 01;18(4):927-932. doi: 10.22034/APJCP.2017.18.4.927. PMID: 28545189; PMCID: PMC5494241.
Copy Download .nbib Format: NLM
Characterization of the Adaptive Amoxicillin Resistance of .

Frontiers in microbiology

Wang J, Guo H, Cao C, Zhao W, Kwok LY, Zhang H, Zhang W.
PMID: 29515561
Front Microbiol. 2018 Feb 20;9:292. doi: 10.3389/fmicb.2018.00292. eCollection 2018.

Amoxicillin is one of the most commonly prescribed antibiotics for bacterial infections and gastrointestinal disorders. To investigate the adaptation of

Cite
Wang J, Guo H, Cao C, et al. Characterization of the Adaptive Amoxicillin Resistance of . Front Microbiol. 2018;9:292doi: 10.3389/fmicb.2018.00292.
Wang, J., Guo, H., Cao, C., Zhao, W., Kwok, L. Y., Zhang, H., & Zhang, W. (2018). Characterization of the Adaptive Amoxicillin Resistance of . Frontiers in microbiology, 9292. https://doi.org/10.3389/fmicb.2018.00292
Wang, Jicheng, et al. "Characterization of the Adaptive Amoxicillin Resistance of ." Frontiers in microbiology vol. 9 (2018): 292. doi: https://doi.org/10.3389/fmicb.2018.00292
Wang J, Guo H, Cao C, Zhao W, Kwok LY, Zhang H, Zhang W. Characterization of the Adaptive Amoxicillin Resistance of . Front Microbiol. 2018 Feb 20;9:292. doi: 10.3389/fmicb.2018.00292. eCollection 2018. PMID: 29515561; PMCID: PMC5826216.
Copy Download .nbib Format: NLM
Non-steroidal anti-inflammatory drugs and antibiotics prescription trends at a central west bank hospital.

Sultan Qaboos University medical journal

Tayem YI, Qubaja MM, Shraim RK, Taha OB, Abu Shkheidem IA, Ibrahim MA.
PMID: 24273668
Sultan Qaboos Univ Med J. 2013 Nov;13(4):567-73. doi: 10.12816/0003317. Epub 2013 Nov 08.

OBJECTIVES: We aimed to reliably describe the pattern of outpatient prescription of non-steroidal anti-inflammatory drugs (NSAIDs) and antibiotics (ATBs) at a central hospital in the West Bank, Palestine.METHODS: This was a retrospective, cross-sectional study investigating a cohort of 2,208...

Cite
Tayem YI, Qubaja MM, Shraim RK, et al. Non-steroidal anti-inflammatory drugs and antibiotics prescription trends at a central west bank hospital. Sultan Qaboos Univ Med J. 2013;13(4):567-73doi: 10.12816/0003317.
Tayem, Y. I., Qubaja, M. M., Shraim, R. K., Taha, O. B., Abu Shkheidem, I. A., & Ibrahim, M. A. (2013). Non-steroidal anti-inflammatory drugs and antibiotics prescription trends at a central west bank hospital. Sultan Qaboos University medical journal, 13(4), 567-73. https://doi.org/10.12816/0003317
Tayem, Yasin I, et al. "Non-steroidal anti-inflammatory drugs and antibiotics prescription trends at a central west bank hospital." Sultan Qaboos University medical journal vol. 13,4 (2013): 567-73. doi: https://doi.org/10.12816/0003317
Tayem YI, Qubaja MM, Shraim RK, Taha OB, Abu Shkheidem IA, Ibrahim MA. Non-steroidal anti-inflammatory drugs and antibiotics prescription trends at a central west bank hospital. Sultan Qaboos Univ Med J. 2013 Nov;13(4):567-73. doi: 10.12816/0003317. Epub 2013 Nov 08. PMID: 24273668; PMCID: PMC3836647.
Copy Download .nbib Format: NLM
Editorial on two chronic low back pain studies: A major change in surgical management of disc disease?.

Surgical neurology international

Pawl R.
PMID: 24340235
Surg Neurol Int. 2013 Oct 29;4:S373-4. doi: 10.4103/2152-7806.120780. eCollection 2013.

In two recent publications, the authors' hypothesis was that Modic type 1 changes seen in patients with chronic low back pain and herniated lumbar discs may be attributed to bacterial infection/inflammation. The first study showed that many herniated discs...

Cite
Pawl R. Editorial on two chronic low back pain studies: A major change in surgical management of disc disease?. Surg Neurol Int. 2013;4:S373-4doi: 10.4103/2152-7806.120780.
Pawl, R. (2013). Editorial on two chronic low back pain studies: A major change in surgical management of disc disease?. Surgical neurology international, 4S373-4. https://doi.org/10.4103/2152-7806.120780
Pawl, Ron. "Editorial on two chronic low back pain studies: A major change in surgical management of disc disease?." Surgical neurology international vol. 4 (2013): S373-4. doi: https://doi.org/10.4103/2152-7806.120780
Pawl R. Editorial on two chronic low back pain studies: A major change in surgical management of disc disease?. Surg Neurol Int. 2013 Oct 29;4:S373-4. doi: 10.4103/2152-7806.120780. eCollection 2013. PMID: 24340235; PMCID: PMC3841939.
Copy Download .nbib Format: NLM
Functional dyspepsia symptom resolution after Helicobacter pylori eradication with two different regimens.

Przeglad gastroenterologiczny

Sarikaya M, Dogan Z, Ergül B, Filik L.
PMID: 24868299
Prz Gastroenterol. 2014;9(1):49-52. doi: 10.5114/pg.2014.40851. Epub 2014 Mar 01.

INTRODUCTION: Functional dyspepsia (FD), a common functional gastrointestinal disorder, has a complex underlying pathophysiological mechanism that involves changes in gastric motility, visceral hypersensitivity, genetic susceptibility, psychosocial factors and Helicobacter pylori infection. Although there are several H. pylori eradication treatments,...

Cite
Sarikaya M, Dogan Z, Ergül B, et al. Functional dyspepsia symptom resolution after Helicobacter pylori eradication with two different regimens. Prz Gastroenterol. 2014;9(1):49-52doi: 10.5114/pg.2014.40851.
Sarikaya, M., Dogan, Z., Ergül, B., & Filik, L. (2014). Functional dyspepsia symptom resolution after Helicobacter pylori eradication with two different regimens. Przeglad gastroenterologiczny, 9(1), 49-52. https://doi.org/10.5114/pg.2014.40851
Sarikaya, Murat, et al. "Functional dyspepsia symptom resolution after Helicobacter pylori eradication with two different regimens." Przeglad gastroenterologiczny vol. 9,1 (2014): 49-52. doi: https://doi.org/10.5114/pg.2014.40851
Sarikaya M, Dogan Z, Ergül B, Filik L. Functional dyspepsia symptom resolution after Helicobacter pylori eradication with two different regimens. Prz Gastroenterol. 2014;9(1):49-52. doi: 10.5114/pg.2014.40851. Epub 2014 Mar 01. PMID: 24868299; PMCID: PMC4027843.
Copy Download .nbib Format: NLM
Antimicrobial susceptibility of Bordetella Avium and Ornithobacterium Rhinotracheale strains from wild and domesticated birds in Hungary.

Acta veterinaria Hungarica

Szabó R, Wehmann E, Magyar T.
PMID: 26599089
Acta Vet Hung. 2015 Dec;63(4):413-24. doi: 10.1556/004.2015.039.

The antimicrobial susceptibility of 19 Bordetella avium and 36 Ornithobacterium rhinotracheale strains was tested by the Kirby-Bauer disk diffusion method, and the minimal inhibitory concentrations (MIC) of amoxicillin, doxycycline and erythromycin were also determined. Most O. rhinotracheale strains were...

Cite
Szabó R, Wehmann E, Magyar T. Antimicrobial susceptibility of Bordetella Avium and Ornithobacterium Rhinotracheale strains from wild and domesticated birds in Hungary. Acta Vet Hung. 2015;63(4):413-24doi: 10.1556/004.2015.039.
Szabó, R., Wehmann, E., & Magyar, T. (2015). Antimicrobial susceptibility of Bordetella Avium and Ornithobacterium Rhinotracheale strains from wild and domesticated birds in Hungary. Acta veterinaria Hungarica, 63(4), 413-24. https://doi.org/10.1556/004.2015.039
Szabó, Réka, et al. "Antimicrobial susceptibility of Bordetella Avium and Ornithobacterium Rhinotracheale strains from wild and domesticated birds in Hungary." Acta veterinaria Hungarica vol. 63,4 (2015): 413-24. doi: https://doi.org/10.1556/004.2015.039
Szabó R, Wehmann E, Magyar T. Antimicrobial susceptibility of Bordetella Avium and Ornithobacterium Rhinotracheale strains from wild and domesticated birds in Hungary. Acta Vet Hung. 2015 Dec;63(4):413-24. doi: 10.1556/004.2015.039. PMID: 26599089.
Copy Download .nbib Format: NLM
Efficacy of Prophylactic use of Antibiotics to Avoid Flare up During Root Canal Treatment of Nonvital Teeth: A Randomized Clinical Trial.

Journal of clinical and diagnostic research : JCDR

Akbar I.
PMID: 25954695
J Clin Diagn Res. 2015 Mar;9(3):ZC08-11. doi: 10.7860/JCDR/2015/12046.5620. Epub 2015 Mar 01.

OBJECTIVES: Flare-up during root canal treatment of non vital teeth is a common clinical incident. The aim of the present study was to assess the effect of prophylactic use of antibiotics to avoid flare up during root canal treatment...

Cite
Akbar I. Efficacy of Prophylactic use of Antibiotics to Avoid Flare up During Root Canal Treatment of Nonvital Teeth: A Randomized Clinical Trial. J Clin Diagn Res. 2015;9(3):ZC08-11doi: 10.7860/JCDR/2015/12046.5620.
Akbar, I. (2015). Efficacy of Prophylactic use of Antibiotics to Avoid Flare up During Root Canal Treatment of Nonvital Teeth: A Randomized Clinical Trial. Journal of clinical and diagnostic research : JCDR, 9(3), ZC08-11. https://doi.org/10.7860/JCDR/2015/12046.5620
Akbar, Iftikhar. "Efficacy of Prophylactic use of Antibiotics to Avoid Flare up During Root Canal Treatment of Nonvital Teeth: A Randomized Clinical Trial." Journal of clinical and diagnostic research : JCDR vol. 9,3 (2015): ZC08-11. doi: https://doi.org/10.7860/JCDR/2015/12046.5620
Akbar I. Efficacy of Prophylactic use of Antibiotics to Avoid Flare up During Root Canal Treatment of Nonvital Teeth: A Randomized Clinical Trial. J Clin Diagn Res. 2015 Mar;9(3):ZC08-11. doi: 10.7860/JCDR/2015/12046.5620. Epub 2015 Mar 01. PMID: 25954695; PMCID: PMC4413145.
Copy Download .nbib Format: NLM
Preparation of hydrophilic nanofiltration membranes for removal of pharmaceuticals from water.

Journal of environmental health science & engineering

Omidvar M, Soltanieh M, Mousavi SM, Saljoughi E, Moarefian A, Saffaran H.
PMID: 25992296
J Environ Health Sci Eng. 2015 May 13;13:42. doi: 10.1186/s40201-015-0201-3. eCollection 2015.

Asymmetric polyethersulfone (PES) nanofiltration membranes were prepared via phase inversion technique. PES polymer, Brij 58 as surfactant additive, polyvinylpyrrolidone (PVP) as pore former and 1-methyl-2-pyrrolidone (NMP) as solvent were used in preparation of the casting solutions. Distillated water was...

Cite
Omidvar M, Soltanieh M, Mousavi SM, et al. Preparation of hydrophilic nanofiltration membranes for removal of pharmaceuticals from water. J Environ Health Sci Eng. 2015;13:42doi: 10.1186/s40201-015-0201-3.
Omidvar, M., Soltanieh, M., Mousavi, S. M., Saljoughi, E., Moarefian, A., & Saffaran, H. (2015). Preparation of hydrophilic nanofiltration membranes for removal of pharmaceuticals from water. Journal of environmental health science & engineering, 1342. https://doi.org/10.1186/s40201-015-0201-3
Omidvar, Maryam, et al. "Preparation of hydrophilic nanofiltration membranes for removal of pharmaceuticals from water." Journal of environmental health science & engineering vol. 13 (2015): 42. doi: https://doi.org/10.1186/s40201-015-0201-3
Omidvar M, Soltanieh M, Mousavi SM, Saljoughi E, Moarefian A, Saffaran H. Preparation of hydrophilic nanofiltration membranes for removal of pharmaceuticals from water. J Environ Health Sci Eng. 2015 May 13;13:42. doi: 10.1186/s40201-015-0201-3. eCollection 2015. PMID: 25992296; PMCID: PMC4437680.
Copy Download .nbib Format: NLM
Congenital broncho-oesophageal fistula: An unusual cause of persistent pneumonia in a young adult.

Respiratory medicine case reports

Savvoula S, Vasiliki P, Kyparisia K, Christina A, Ioannis M, Athanasios K.
PMID: 26029609
Respir Med Case Rep. 2013 Jan 12;8:21-4. doi: 10.1016/j.rmcr.2012.12.003. eCollection 2013.

A 19-year-old female with a 3-day history of high temperature, productive cough and dyspnoea was admitted due to diabetic ketoacidosis and pneumonia of the right lower lobe. Antibiotics (amoxicillin-clavulanic acid), insulin, fluids and electrolytes were administered, as appropriate. The...

Cite
Savvoula S, Vasiliki P, Kyparisia K, et al. Congenital broncho-oesophageal fistula: An unusual cause of persistent pneumonia in a young adult. Respir Med Case Rep. 2013;8:21-4doi: 10.1016/j.rmcr.2012.12.003.
Savvoula, S., Vasiliki, P., Kyparisia, K., Christina, A., Ioannis, M., & Athanasios, K. (2013). Congenital broncho-oesophageal fistula: An unusual cause of persistent pneumonia in a young adult. Respiratory medicine case reports, 821-4. https://doi.org/10.1016/j.rmcr.2012.12.003
Savvoula, Savvidou, et al. "Congenital broncho-oesophageal fistula: An unusual cause of persistent pneumonia in a young adult." Respiratory medicine case reports vol. 8 (2013): 21-4. doi: https://doi.org/10.1016/j.rmcr.2012.12.003
Savvoula S, Vasiliki P, Kyparisia K, Christina A, Ioannis M, Athanasios K. Congenital broncho-oesophageal fistula: An unusual cause of persistent pneumonia in a young adult. Respir Med Case Rep. 2013 Jan 12;8:21-4. doi: 10.1016/j.rmcr.2012.12.003. eCollection 2013. PMID: 26029609; PMCID: PMC3920443.
Copy Download .nbib Format: NLM
Global Phenotypic Characterization of Effects of Fluoroquinolone Resistance Selection on the Metabolic Activities and Drug Susceptibilities of Clostridium perfringens Strains.

International journal of microbiology

Park M, Rafii F.
PMID: 25587280
Int J Microbiol. 2014;2014:456979. doi: 10.1155/2014/456979. Epub 2014 Dec 21.

Fluoroquinolone resistance affects toxin production of Clostridium perfringens strains differently. To investigate the effect of fluoroquinolone resistance selection on global changes in metabolic activities and drug susceptibilities, four C. perfringens strains and their norfloxacin-, ciprofloxacin-, and gatifloxacin-resistant mutants were...

Cite
Park M, Rafii F. Global Phenotypic Characterization of Effects of Fluoroquinolone Resistance Selection on the Metabolic Activities and Drug Susceptibilities of Clostridium perfringens Strains. Int J Microbiol. 2014;2014:456979doi: 10.1155/2014/456979.
Park, M., & Rafii, F. (2014). Global Phenotypic Characterization of Effects of Fluoroquinolone Resistance Selection on the Metabolic Activities and Drug Susceptibilities of Clostridium perfringens Strains. International journal of microbiology, 2014456979. https://doi.org/10.1155/2014/456979
Park, Miseon, and Rafii, Fatemeh. "Global Phenotypic Characterization of Effects of Fluoroquinolone Resistance Selection on the Metabolic Activities and Drug Susceptibilities of Clostridium perfringens Strains." International journal of microbiology vol. 2014 (2014): 456979. doi: https://doi.org/10.1155/2014/456979
Park M, Rafii F. Global Phenotypic Characterization of Effects of Fluoroquinolone Resistance Selection on the Metabolic Activities and Drug Susceptibilities of Clostridium perfringens Strains. Int J Microbiol. 2014;2014:456979. doi: 10.1155/2014/456979. Epub 2014 Dec 21. PMID: 25587280; PMCID: PMC4283427.
Copy Download .nbib Format: NLM
Clarithromycin vs. Gemifloxacin in Quadruple Therapy Regimens for Empiric Primary Treatment of Helicobacter pylori Infection: A Randomized Clinical Trial.

Middle East journal of digestive diseases

Masoodi M, Talebi-Taher M, Tabatabaie K, Khaleghi S, Faghihi AH, Agah S, Asadi R.
PMID: 26106468
Middle East J Dig Dis. 2015 Apr;7(2):88-93.

BACKGROUND Eradication of Helicobacter pylori infection plays a crucial role in the treatment of peptic ulcer. Clarithromycin resistance is a major cause of treatment failure. This randomized clinical trial aimed at evaluating the efficacy of a clarithromycin versus gemifloxacin...

Cite
Masoodi M, Talebi-Taher M, Tabatabaie K, et al. Clarithromycin vs. Gemifloxacin in Quadruple Therapy Regimens for Empiric Primary Treatment of Helicobacter pylori Infection: A Randomized Clinical Trial. Middle East J Dig Dis. 2015;7(2):88-93
Masoodi, M., Talebi-Taher, M., Tabatabaie, K., Khaleghi, S., Faghihi, A. H., Agah, S., & Asadi, R. (2015). Clarithromycin vs. Gemifloxacin in Quadruple Therapy Regimens for Empiric Primary Treatment of Helicobacter pylori Infection: A Randomized Clinical Trial. Middle East journal of digestive diseases, 7(2), 88-93.
Masoodi, Mohsen, et al. "Clarithromycin vs. Gemifloxacin in Quadruple Therapy Regimens for Empiric Primary Treatment of Helicobacter pylori Infection: A Randomized Clinical Trial." Middle East journal of digestive diseases vol. 7,2 (2015): 88-93.
Masoodi M, Talebi-Taher M, Tabatabaie K, Khaleghi S, Faghihi AH, Agah S, Asadi R. Clarithromycin vs. Gemifloxacin in Quadruple Therapy Regimens for Empiric Primary Treatment of Helicobacter pylori Infection: A Randomized Clinical Trial. Middle East J Dig Dis. 2015 Apr;7(2):88-93. PMID: 26106468; PMCID: PMC4430797.
Copy Download .nbib Format: NLM
Showing 13 to 24 of 1876 entries